FirstIgnite is supporting the commercialization of the University of California Davis’s new technology for the relief of chronic and/or severe pain. The benefits of this technology are the optimization of wild-type ProTx-II peptide selectivity and potency and a non-addictive alternative to opioid analgesics.

This technology can be applied to the relief of chronic and/or severe pain in humans. As of 2021, the U.S. pain management therapeutics market is worth $6.75 billion and is expected to reach $12.55 billion by 2028. 

The University of California Davis’s technology for the relief of chronic and/or severe pain is ready for collaboration, and they are looking for industry feedback on their research and potential future collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of California Davis team, you can schedule a time directly on their team’s calendar here.